dalteparin has been researched along with Adenocarcinoma, Alveolar in 1 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Colagiovanni, A | 1 |
| Rizzi, A | 1 |
| Buonomo, A | 1 |
| De Pasquale, T | 1 |
| Pecora, V | 1 |
| Sabato, V | 1 |
| Aruanno, A | 1 |
| Pascolini, L | 1 |
| Nucera, E | 1 |
| Schiavino, D | 1 |
1 other study available for dalteparin and Adenocarcinoma, Alveolar
| Article | Year |
|---|---|
Delayed hypersensitivity to heparin in a patient with cancer: fondaparinux may be safe but needs to be tested.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adrenal Cortex Hormones; Anticoagulants; Breast Neoplasms; Drug | 2010 |